中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

蛋白激酶CK2β在肝细胞癌中的表达及临床意义

梁润威 范正军 黄娟 孙涛 余祖启

引用本文:
Citation:

蛋白激酶CK2β在肝细胞癌中的表达及临床意义

DOI: 10.3969/j.issn.1001-5256.2019.03.019
基金项目: 

河南省科技攻关项目(182102310143); 

详细信息
  • 中图分类号: R735.7

Expression and clinical significance of protein kinase CK2β in hepatocellular carcinoma

Research funding: 

 

  • 摘要: 目的研究蛋白激酶CK2β在肝细胞癌组织中的表达及临床意义,并探讨其表达与患者预后的关系。方法收集2012年1月-2013年6月于郑州大学第一附属医院肝胆胰外科确诊的127例肝细胞癌患者癌组织及癌旁组织,采用免疫组化法检测其CK2β的表达,分析癌组织中CK2β表达强度与肝癌患者临床特征的关系。另收集本院2018年3-6月期间手术切除的20例肝细胞癌癌组织、癌旁组织、肝硬化组织、正常肝组织标本并提取蛋白和mRNA,运用Westen Blot和real-time PCR检测其CK2β表达情况。多组间均数比较采用单因素方差分析,进一步两两比较采用Bonferroni检验,计数资料组间比较采用χ2检验。CK2β在肝细胞癌的表达差异与临床特征参数的关系采用Mann-Whitney U检验或Kruskal-Wallis H检验。生存分析采用Kaplan-Meier法,组间比较采用log-rank检验。结果 Westen Blot和real-time PCR结果证实CK2β在癌组织中表达率显著高于癌旁组织、肝硬化组织和正常肝组织(P值均<0. 05);癌旁及肝硬化组织中CK2β表达无差异(P值均...

     

  • [1] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics inChina, 2015[J]. CA Cancer J Clin, 2016, 66 (2) :115-132.
    [2] National Health and Family Planning Commission of the People'sRepublic of China. Diagnosis, management, and treatment ofhepatocellular carcinoma (V2017) [J]. J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.
    [3] SHARIFF MI, COX IJ, GOMAA AI, et al. Hepatocellular carci-noma:Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics[J]. Expert Rev GastroenterolHepatol, 2009, 3 (4) :353-367.
    [4] DUNCAN JS, LITCHFIELD DW. Too much of a good thing:The role of protein kinase CK2 in tumorigenesis and prospectsfor therapeutic inhibition of CK2[J]. Biochim Biophys Acta, 2008, 1784 (1) :33-47.
    [5] RUZZENE M, PINNA LA. Addiction to protein kinase CK2:Acommon denominator of diverse cancer cells[J]. Biochim Bio-phys Acta, 2010, 1804 (3) :499-504.
    [6] KIM S, HAM S, YANG K, et al. Protein kinase CK2 activationis required for transforming growth factor beta-induced epi-thelial-mesenchymal transition[J]. Mol Oncol, 2018, 12 (10) :1811-1826.
    [7] GUERRA B, ISSINGER OG. Protein kinase CK2 and its role incellular proliferation, development and pathology[J]. Electro-phoresis, 2015, 20 (2) :391-408.
    [8] BROWN MS, DIALLO OT, HU M, et al. CK2 modulation of NF-kappaB, TP53 and the malignant phenotype in head andneck cancer by anti-CK2 oligonucleotides in vitro or in vivovia sub-50 nm nanocapsules[J]. Clin Cancer Res, 2010, 16 (8) :2295-2307.
    [9] BLIESATH J, HUSER N, OMORI M, et al. Combined inhibitionof EGFR and CK2 augments the attenuation of PI3K-Akt-m TOR signaling and the killing of cancer cells[J]. Cancer Let-ters, 2012, 322 (1) :113-118.
    [10] CHEN WY, REN N. Advances in molecular targeted therapyfor hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34 (7) :1387-1394. (in Chinese) 陈万勇, 任宁.肝细胞癌分子靶向治疗进展[J].临床肝胆病杂志, 2018, 34 (7) :1387-1394.
    [11] BUONTEMPO F, MCCUBREY JA, ORSINI E, et al. Therapeu-tic targeting of CK2 in acute and chronic leukemias[J]. Leu-kemia, 2017, 32 (1) :1-10.
    [12] GOWDA C, SACHDEV M, MUTHISAMI S, et al. Casein ki-naseⅡ (CK2) as a therapeutic target for hematological malig-nancies[J]. Curr Pharm Des, 2017, 23 (1) :95-107.
    [13] FILHOL O, NUEDA A, MARTEL V, et al. Live-cell fluores-cence imaging reveals the dynamics of protein kinase CK2 in-dividual subunits[J]. Mol Cell Biol, 2003, 23 (3) :975-987.
    [14] BIBBY AC, LITCHFIELD DW. The multiple personalities of theregulatory subunit of protein kinase CK2:CK2 dependent andCK2 independent roles reveal a secret identity for CK2beta[J]. Int J Biol Sci, 2005, 1 (2) :67-79.
    [15] GOLDEN D, CANTLEY LG. Casein kinase 2 prevents mesen-chymal transformation by maintaining Foxc2 in the cytoplasm[J]. Oncogene, 2015, 34 (36) :4702-4712.
    [16] DESHIERE A, DUCHEMINPELLETIER E, SPREUX E, et al.Unbalanced expression of CK2 kinase subunits is sufficient todrive epithelial-to-mesenchymal transition by Snail1 induc-tion[J]. Oncogene, 2013, 32 (11) :1373-1383.
    [17] VOLODINA YL, SHTIL AA. Casein kinase 2, a versatile regu-lator of cell surviva[J]. Mol Biol (Mosk) , 2012, 46 (3) :381-390.
    [18] BIBBY AC, LITCHFIELD DW. The multiple personalities of theregulatory subunit of protein kinase CK2:CK2 dependent andCK2 independent roles reveal a secret identity for CK2β[J]. IntJ Biol Sci, 2005, 1 (2) :67-79.
    [19] ZOU JJ, LUO HS, HUANG ZY, et al. Correlation of casein ki-nase 2βoverexpression to the metastatic ability of colorectalcancer cells in vitro[J]. J South Med Univ, 2011, 31 (4) :628-632. (in Chinese) 邹金金, 罗何三, 黄志勇, 等.高表达Ck2β与大肠癌发生和转移的相关性研究[J].南方医科大学学报, 2011, 31 (4) :628-632.
    [20] CHEN B, CAO ZY, CAO CH, et al. Effect of casein kinase 2βin esophageal carcinoma and its clinical significance[J]. JSouth Med Univ, 2012, 32 (10) :1491-1494, 1497. (in Chi-nese) 陈勃, 曹忠宜, 曹传辉, 等.蛋白激酶CK2β在食管癌中的表达及其临床意义[J].南方医科大学学报, 2012, 32 (10) :1491-1494, 1497.
    [21] VILARDELL J, ALCARAZ E, SARRE, et al. Under-expres-sion of CK2βsubunit in ccRCC represents a complementarybiomarker of p-STAT3 Ser727 that correlates with patient sur-vival[J]. Oncotarget, 2018, 9 (5) :5736-5751.
    [22] LIN KY, FANG CL, CHEN Y, et al. Overexpression of nuclearprotein kinase CK2 Beta subunit and prognosis in human gas-tric carcinoma[J]. Ann Surg Oncol, 2010, 17 (6) :1695-1702.
    [23] FILHOL O, GIACOSA S, WALLEZ Y, et al. Protein kinase CK2in breast cancer:The CK2βregulatory subunit takes centerstage in epithelial plasticity[J]. Cell Mol Life Sci, 2015, 72 (17) :3305-3322.
    [24] KIM S, HAM S, YANG K, et al. Protein kinase CK2 activationis required for transforming growth factorβ-induced epithelial-mesenchymal transition[J]. Mol Oncol, 2018, 12 (10) :1811-1826.
    [25] MIKULITS W. Epithelial to mesenchymal transition in hepato-cellular carcinoma[J]. Future Oncol, 2018, 5 (8) :1169.
  • 加载中
计量
  • 文章访问数:  1288
  • HTML全文浏览量:  14
  • PDF下载量:  294
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-10-24
  • 出版日期:  2019-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回